Cancer Systems Biology: a peek into the future of patient care?
暂无分享,去创建一个
Prahlad T. Ram | Gordon B. Mills | G. Mills | P. Ram | H. Werner | Henrica M. J. Werner | H. M. Werner
[1] Tyler J Moss,et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells , 2012, Molecular systems biology.
[2] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[3] A. Edwards,et al. Leveraging Crowdsourcing to Facilitate the Discovery of New Medicines , 2011, Science Translational Medicine.
[4] Paul A. Wiggins,et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state , 2011, Proceedings of the National Academy of Sciences.
[5] Robert J. Gillies,et al. Current Advances in Mathematical Modeling of Anti-Cancer Drug Penetration into Tumor Tissues , 2013, Front. Oncol..
[6] S. Friend,et al. Developing predictive molecular maps of human disease through community-based modeling , 2011, Nature Genetics.
[7] Eytan Domany,et al. A module of negative feedback regulators defines growth factor signaling , 2007, Nature Genetics.
[8] S. Gygi,et al. Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. , 2011, Molecular cell.
[9] R. Cardiff,et al. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell of origin model for prostate cancer heterogeneity , 2013, Nature Cell Biology.
[10] David E. Housman,et al. Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines , 2013, PloS one.
[11] D. Lauffenburger,et al. Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress , 2012, Molecular systems biology.
[12] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[13] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[14] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[15] David Haussler,et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling , 2011, Proceedings of the National Academy of Sciences.
[16] Bahram Parvin,et al. Linking Changes in Epithelial Morphogenesis to Cancer Mutations Using Computational Modeling , 2010, PLoS Comput. Biol..
[17] P. Spellman,et al. Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.
[18] H. Ohtsuki,et al. Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.
[19] Joshua C. Gilbert,et al. An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.
[20] Ken Ito,et al. An Integrated Computational/Experimental Model of Lymphoma Growth , 2013, PLoS Comput. Biol..
[21] J. Lowengrub,et al. Multispecies model of cell lineages and feedback control in solid tumors. , 2012, Journal of theoretical biology.
[22] Mechthild Krause,et al. Three-dimensional cell growth confers radioresistance by chromatin density modification. , 2010, Cancer research.
[23] J. Larkin,et al. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies , 2011, British Journal of Cancer.
[24] Ernesto S. Nakayasu,et al. Model-driven multi-omic data analysis elucidates metabolic immunomodulators of macrophage activation , 2012, Molecular systems biology.
[25] Sean C. Bendall,et al. Extracting a Cellular Hierarchy from High-dimensional Cytometry Data with SPADE , 2011, Nature Biotechnology.
[26] G. Whitesides. The origins and the future of microfluidics , 2006, Nature.
[27] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[28] C. Sautès-Fridman,et al. Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin , 2013, Clinical Cancer Research.
[29] Gregory Stephanopoulos,et al. The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4 , 2013, Cell.
[30] P. Dijke,et al. TGF-β signalling and its role in cancer progression and metastasis , 2012, Cancer and Metastasis Reviews.
[31] C. Sander,et al. Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.
[32] G. Mills,et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer , 2012, Genome research.
[33] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[34] J. Settleman,et al. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.
[35] Genee Y. Lee,et al. The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expression , 2007, Molecular oncology.
[36] M. Loda,et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer , 2013, Nature Genetics.
[37] Daniel Gallahan,et al. Systems biology: confronting the complexity of cancer. , 2011, Cancer research.
[38] Alexander R A Anderson,et al. Quantifying the Role of Angiogenesis in Malignant Progression of Gliomas: in Silico Modeling Integrates Imaging and Histology Nih Public Access Author Manuscript Introduction , 2011 .
[39] Melissa H Wong,et al. Tumor microenvironment complexity: emerging roles in cancer therapy. , 2012, Cancer research.
[40] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.
[41] Ulrik B. Nielsen,et al. Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 , 2012, Molecular Cancer Therapeutics.
[42] Andrea Califano,et al. Reverse‐engineering human regulatory networks , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.
[43] Ajay N. Jain,et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.
[44] Razelle Kurzrock,et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Chaplain,et al. Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. , 2009, Cancer research.
[46] E. Lengyel,et al. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra‐cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum , 2007, International journal of cancer.
[47] P. Sorger,et al. Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.
[48] D. Vitkup,et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network , 2013, Nature Biotechnology.
[49] Yiling Lu,et al. Systematic analysis of genotype‐specific drug responses in cancer , 2012, International journal of cancer.
[50] G. Mills,et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.
[51] C. Iacobuzio-Donahue,et al. Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies , 2012, Cell.
[52] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[53] A. Califano,et al. STK38 is a critical upstream regulator of MYC’s oncogenic activity in human B-cell lymphoma , 2013, Oncogene.
[54] Douglas A Lauffenburger,et al. A mammalian functional-genetic approach to characterizing cancer therapeutics. , 2010, Nature chemical biology.
[55] Chen-Hsiang Yeang,et al. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer , 2012, Proceedings of the National Academy of Sciences.
[56] J. Uhm,et al. The transcriptional network for mesenchymal transformation of brain tumours , 2010 .
[57] A. Trumpp,et al. What does the concept of the stem cell niche really mean today? , 2012, BMC Biology.
[58] Lewis C Cantley,et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.
[59] Vittorio Cristini,et al. Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements , 2013, Proceedings of the National Academy of Sciences.
[60] K. Coombes,et al. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers , 2010, Clinical Proteomics.
[61] Philip E. Bourne,et al. Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..
[62] Michael Peyton,et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.
[63] P. Hahnfeldt,et al. Cancer Stem Cells: A Minor Cancer Subpopulation that Redefines Global Cancer Features , 2013, Front. Oncol..
[64] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[65] Yiling Lu,et al. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.
[66] Xuerui Yang,et al. An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma , 2011, Cell.
[67] G. Collins. The next generation. , 2006, Scientific American.
[68] Mark A. J. Chaplain,et al. Mathematical modeling of cancer cell invasion of tissue: biological insight from mathematical analysis and computational simulation , 2011, Journal of mathematical biology.
[69] I. Mackenzie,et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. , 2011, Cancer research.
[70] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[71] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[72] Maqc Consortium. The MicroArray Quality Control ( MAQC )-II study of common practices for the development and validation of microarray-based predictive models , 2012 .
[73] Mingsheng Zhang,et al. Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. , 2011, Cancer research.
[74] Joshua M. Stuart,et al. Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.
[75] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[76] H. Woo,et al. Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis , 2011, Proceedings of the National Academy of Sciences.
[77] William C Reinhold,et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.
[78] Luke A. Gilbert,et al. Defining principles of combination drug mechanisms of action , 2012, Proceedings of the National Academy of Sciences.
[79] Terence P. Speed,et al. Bayesian Inference of Signaling Network Topology in a Cancer Cell Line , 2012, Bioinform..
[80] Adam A. Margolin,et al. Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer , 2013, Science Translational Medicine.
[81] R. Bernards,et al. Understanding resistance to targeted cancer drugs through loss of function genetic screens. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[82] Thomas E Yankeelov,et al. Clinically Relevant Modeling of Tumor Growth and Treatment Response , 2013, Science Translational Medicine.
[83] Guy S. Salvesen,et al. SnapShot: Caspases , 2011, Cell.
[84] E. Danen,et al. Cross-Talk between Integrins and Oncogenes Modulates Chemosensitivity , 2009, Molecular Pharmacology.
[85] Thomas Streichert,et al. Genome-Wide Gene Expression Analysis in Cancer Cells Reveals 3D Growth to Affect ECM and Processes Associated with Cell Adhesion but Not DNA Repair , 2012, PloS one.
[86] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[87] Luay Nakhleh,et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling , 2011, Oncogene.
[88] L. Chin,et al. Making sense of cancer genomic data. , 2011, Genes & development.
[89] A. Ashworth,et al. Emerging therapeutic targets in endometrial cancer , 2011, Nature Reviews Clinical Oncology.
[90] Lei Zhang,et al. A reaction–diffusion mechanism influences cell lineage progression as a basis for formation, regeneration, and stability of intestinal crypts , 2012, BMC Systems Biology.
[91] Karen Sachs,et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators , 2012, Nature Biotechnology.
[92] Erhan Bilal,et al. Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling , 2013, PLoS Comput. Biol..
[93] V. Grantcharova,et al. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.
[94] Daniel C Kirouac,et al. Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.
[95] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[96] Gavin MacBeath,et al. Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks , 2013, Science Signaling.
[97] G. Mills. An emerging toolkit for targeted cancer therapies. , 2012, Genome research.
[98] D. Lauffenburger,et al. Networks Inferred from Biochemical Data Reveal Profound Differences in Toll-like Receptor and Inflammatory Signaling between Normal and Transformed Hepatocytes* , 2010, Molecular & Cellular Proteomics.
[99] Q. Nie,et al. Cell Lineages and the Logic of Proliferative Control , 2009, PLoS biology.
[100] J. Rich,et al. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] W. Schiemann,et al. Transforming growth factor-β and the hallmarks of cancer. , 2011, Cellular signalling.
[102] Ernest Fraenkel,et al. Linking Proteomic and Transcriptional Data through the Interactome and Epigenome Reveals a Map of Oncogene-induced Signaling , 2013, PLoS Comput. Biol..
[103] John G. Albeck,et al. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. , 2013, Molecular cell.
[104] Zhi Hu,et al. Integrated analysis of breast cancer cell lines reveals unique signaling pathways , 2009, Genome Biology.
[105] V. Quaranta,et al. Fractional Proliferation: A method to deconvolve cell population dynamics from single-cell data , 2012, Nature Methods.